ASX Share rice
Tue 18 May 2021 - 12:00:pm (Sydney)

MXC Share Price

MGC PHARMACEUTICALS LTDMXCPharmaceuticals, Biotechnology & Life Sciences

MXC Company Information


MGC Pharmaceuticals Limited




Drug Manufacturers-Specialty & Generic

GIC Industry:


GIC Sub Industry:



1202 Hay Street West Perth WA Australia 6005


61 8 6382 3390

Exec. Chairman:

Mr. Brett Anthony Mitchell

Co-Founder, CEO, MD & Exec. Director:

Mr. Roby Reuven Zomer

Founder & Non-Exec. Director:

Mr. Nativ Segev

Chief Financial Officer:

Mr. Daniel Kendall

Chief Research Officer:

Dr. Nadya Lisodover

CTO & Head of Pharmaceutical Production:

Mr. Amir Polak

Global Chief Sales Officer:

Ms. Nicole Godresse

Head of the Quality Assurance Department:

Ms. Sabina Suljakovic

Company Sec. (Leave of Absence):

Ms. Rachel Jelleff Kerr

Chief Exec. Officer of MGC Derma:

Hugh Winters

Company Overview:

MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.

MXC Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


MXC CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Borrowings:


Net Income:


Total Cash From Operating Activities:




Other Cashflow From Investing Activities:


Change To Inventory:


Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


MXC Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Other Operating Expenses:


Interest Expense:


Total Revenue:


Cost Of Revenue:


MXC Balance Sheet

Balance Sheet Date:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:


Other Liabilities:




Total Current Liabilities:


Property - Plant & Equipment:


Net Tangible Assets:


Long-Term Investments:


Total Current Assets:


Net Receivables:


Short-Term Investments:




Accounts Payable:


Non Currrent Assets (Other):


Short-Term Investments:


Non Current Liabilities Total:


MXC Share Price History

MXC News

30 Dec, 2020
Roby Zomer has been the CEO of MGC Pharmaceuticals Limited ( ASX:MXC ) since 2016, and this article will examine the...
19 Jun, 2020
Under the terms of this agreement, MGC Pharma will provide a comprehensive suite of pharmaceutical services to advance Allied’s pharmaceutical products into human clinical PHASE 1. The scope of MGC Pharma’s services will cover clinical research, IMP registration, manufacturing of lab volumes for the research project, drug stability testing, GMP manufacturing and regulatory assistance for obtaining an Investigational Medicinal Product (IMP) number that is needed in order to sell the pharmaceutical product. Allied has also conducted an extensive prior art review on its previously submitted provisional patents for products AC001 and AC002 and has decided to abandon these.
15 Jun, 2020
TORONTO and GLIL YAM, Israel , June 15, 2020 /CNW/ - IM Cannabis Corp. (the "Company" or "IMC") (IMCC.CN), one of the world's pioneering medical cannabis companies with operations in Israel and across Europe , today announced that the Company has signed a binding term sheet for the exclusive distribution rights of CannEpil® in Israel for a period of five years (the "Term Sheet"). The Term Sheet follows the announcement by MGC on May 26, 2020 that the Ethics Committee of Schneider Children's Medical Center of Israel has given its approval to commence a Phase IIb clinical trial of CannEpil® in Israel .
27 May, 2020
In addition to this, through the MGC sales and distribution agreement, Allied will be able to sell their products following the completion of the PHASE I clinical trial. MGC currently has cannabis-based pharmaceutical products for sale in Europe and has demonstrated a proven ability to commercialize cannabis based pharmaceutical products.